Results 231 to 240 of about 244,160 (267)

United States Food and Drug Administration requirements for approval of generic drug products.

The Journal of clinical psychiatry, 2001
As generic products become more available for the treatment of psychiatric disorders, clinicians must stay abreast of the U.S. Food and Drug Administration (FDA) requirements for the approval of generic drug products. The FDA declares that pharmaceutical equivalents only are therapeutically equivalent, and pharmacokinetic data are all that is usually ...
openaire   +1 more source

Retrospective analysis of adverse events with dupilumab reported to the United States Food and Drug Administration

Journal of the American Academy of Dermatology, 2021
Joseph L Jorizzo
exaly  

United States food and drug administration

2020
openaire   +1 more source

United States Food and Drug Administration TASS Program

Ophthalmology, 2013
openaire   +2 more sources

Adverse events of after-loading high dose rate brachytherapy reported to the United States Food and Drug Administration (FDA)

Brachytherapy, 2021
Murray Loew, Neil Taunk, Sharad Goyal
exaly  

Data from the United States Food and Drug Administration

JAIDS Journal of Acquired Immune Deficiency Syndromes, 2005
openaire   +2 more sources

United States Food and Drug Administration’s authorization of reduced exposure claims for IQOS®: implications for regulation in Latin America

Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2022
Eric Crosbie, Gianella Severini, Sebrié Ernesto M   +2 more
exaly  

Disparities in liver cancer occurrence in the United States by race/ethnicity and state

Ca-A Cancer Journal for Clinicians, 2017
, Ahmedin Jemal, Elizabeth Ward
exaly  

The Regulation of Acupuncture Needles by The United States Food and Drug Administration

The Journal of Alternative and Complementary Medicine, 1995
openaire   +2 more sources

Impact of United States Food and Drug Administration's boxed warnings on adverse drug reactions reporting rates and risk mitigation for multiple myeloma drugs

Expert Opinion on Drug Safety, 2013
Steven Belknap, Cara Karper, Beatrice Edwards   +2 more
exaly